Breast cancer in the era of precision medicine

Sarhangi, Negar; Hajjari, Shahrzad; Heydari, Seyede Fatemeh; Ganjizadeh, Maryam; Rouhollah, Fatemeh; Hasanzad, Mandana

doi:10.1007/s11033-022-07571-2

Cited by 56 publications

(28 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Animal weights and tumor sizes were recorded everyday after drug administration. The tumor volumes were calculated as: tumor volume = 0.5 9 (length) 9 (width) 2 . Mice were killed 28 days post-injection.…”

Section: Xenograft Model Of Breast Cancerstudiesmentioning

confidence: 99%

“…Breast cancer is a heterogeneous disease and can be classified into three main subtypes based on histological and molecular characteristics [2]. Hormone‐receptor positive breast cancer (about 70% of all breast cancer) expresses estrogen receptors (ER) and/or progesteron receptors (PR) and is categorized as luminal A and lumina based on ER, PR, HER2 and Ki‐67 expression levels.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SLC35A2 expression drives breast cancer progression via ERK pathway activation

Yang,

Tao,

et al. 2024

The FEBS Journal

View full text Add to dashboard Cite

Alterations in glycosylation are associated with breast tumor formation and progression. Nevertheless, the specific functions and mechanisms of the human major UDP‐galactose transporter‐encoding gene Solute carrier family 35 member A2 (SLC35A2) in breast invasive carcinoma (BRCA) have not been fully determined. Here we reportthat SLC35A2promotesBRCA progression via activating ERK. SLC35A2 expression and prognosis‐predictive significance in pan‐cancer were evaluated using publicdatabases. The upstream non‐coding RNAs (ncRNAs) of SLC35A2 were analyzed, and their expressions and regulations were validated in breast tissues and cell lines by quantitative polymerase chain reaction (qPCR) and dual‐luciferase assays. We used bioinformatic tools to assess the link between SLC35A2 expression and immune infiltration, and performed immunohistochemistry for validation. CCK8, EdU, transwell, flow cytometer, and westernblottingwere used to assess the proliferation, motility, cell cycleand apoptosis of BRCA cells in vitro. The xenograft models were constructed to assess the effect of SLC35A2 on BRCA tumor growth in vivo. The results indicated thatSLC35A2 expression was upregulated and linked to an unfavorable prognosis in BRCA. The most likely upstream ncRNA‐associated pathway of SLC35A2 in BRCA was the AC074117.1/hsa‐let‐7b‐5p axis. SLC35A2 expression had positive correlations with the presence of Th2 cells, regulatory T cells, and immune checkpoints. Knockdown ofSLC35A2could reduce BRCA cell proliferation, motility, and cause G2/M arrest and cell apoptosis via ERK signaling. Moreover, ERK activation can rescue the inhibitory effects of knockdownSLC35A2in BRCA. In conclusion, AC074117.1/hsa‐let‐7b‐5p axis‐mediated high expression of SLC35A2 acts as a tumor promoter in BRCA via ERK signaling, which provides a potential target for BRCA treatment.

show abstract

Section: Xenograft Model Of Breast Cancerstudiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

SLC35A2 expression drives breast cancer progression via ERK pathway activation

Yang,

Tao,

et al. 2024

The FEBS Journal

View full text Add to dashboard Cite

show abstract

“…It severely affects the quality of life and health of women. − For a long time, chemotherapy has been the main treatment method . However, conventional chemotherapy drugs usually involve systemic toxicity, which causes a great extent of damage to the normal cells. , Therefore, the development of multifunctional nanodrug delivery system is of much interest …”

Section: Introductionmentioning

confidence: 99%

“…4 However, conventional chemotherapy drugs usually involve systemic toxicity, which causes a great extent of damage to the normal cells. 5,6 Therefore, the development of multifunctional nanodrug delivery system is of much interest. 7 The metal−organic frame material the zeolite imidazolate frame (ZIF), which has good thermal stability, a large aperture, and a large surface area, is frequently employed in support design.…”

Section: ■ Introductionmentioning

confidence: 99%

Gold-Aptamer-Modified Metal–Organic Framework Drug Delivery Nanosystems for Combined Photothermal/Chemotherapy of Cancer

Fang,

Duan,

Wan

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

The poor targeting and high toxicity of chemotherapeutic drugs make them less effective against breast cancer. In this study, in accordance with their photothermal effect, the aptamer (Apt) (AS1411) and doxorubicin (DOX) were linked to zeolite imidazole salt frame8 (ZIF-8) by using gold nanorods (Au NRs). Thereby, a multifunctional targeting nanoparticle platform (DOX/Au-Apt@ZIF-8) was constructed to deliver and effectively utilize DOX and realize the antitumor effects of the multimodal combination of chemotherapy−target−photothermal therapy. This platform was responsive to both pH and near-infrared (NIR) light.

show abstract

“…These differences are clear in the expression of tumor markers, tumor genomics, staging, tumor pathology, patient genetics and demographics, and the tumor microenvironment and immune environment. 2 As such, we practice individualized breast cancer care, taking these factors into account in developing treatment pathways for each patient in the clinical setting. Accordingly, this diversity should also be considered in study design to optimize trial results and potential applicability, especially given all of the resources that must go into such a trial.…”

mentioning

confidence: 99%

Assessment of Novel Therapeutics for Individualized Breast Cancer Care in the Modern Era: The Role of Metformin in Breast Cancer Therapy

Postlewait

2022

Ann Surg Oncol

View full text Add to dashboard Cite

Breast cancer in the era of precision medicine

Cited by 56 publications

References 95 publications

SLC35A2 expression drives breast cancer progression via ERK pathway activation

SLC35A2 expression drives breast cancer progression via ERK pathway activation

Gold-Aptamer-Modified Metal–Organic Framework Drug Delivery Nanosystems for Combined Photothermal/Chemotherapy of Cancer

Assessment of Novel Therapeutics for Individualized Breast Cancer Care in the Modern Era: The Role of Metformin in Breast Cancer Therapy

Contact Info

Product

Resources

About